Could a Cancer Drug Be Repurposed for Fragile X Syndrome? (IMAGE)

American Association for the Advancement of Science (AAAS)

Could a Cancer Drug Be Repurposed for Fragile X Syndrome?

Caption

This is a schematic diagram showing the stages of neurogenesis in the adult dentate gyrus of the hippocampus and cell lineage-specific markers. qNSC, quiescent NSC; aNSC, activated NSC. This material relates to a paper that appeared in the April 27, issue of <i>Science Translational Medicine</i>, published by AAAS. The paper, by Y. Li at University of Wisconsin-Madison in Madison, WI, and colleagues was titled, "MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome."

Credit

Li <i>et al., Science Translational Medicine</i> (2016)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.